The fixed-effects model meta-analysis revealed that preoperative use of SGLT2 inhibitors significantly reduced HF readmission rates (OR = 0.30, 95% CI: [0.16, 0.56], P = .0001), with statistically significant results. The gene discussed is SLC5A2; the disease is hydrops fetalis.